Serum erythropoietin levels in patients with solid tumours

Kettelhack, C.; Schöter, D; Matthias, D.; Schlag, Peter M.

doi:10.1016/0959-8049(94)90175-9

Cited by 8 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicates an increased erythropoiesis in melanoma affected minipigs. This is contradictory to findings of Kettelhack et al (1994) reported from human patients with solid tumours. Although the authors reported that serum erythropoietin (EPO) was clearly elevated in anaemic tumour patients, the levels of EPO in tumour patients without anaemia were decreased.…”

Section: Development Of Haematological Indices In Group Acontrasting

confidence: 56%

See 1 more Smart Citation

Development of Haematological Indices in Melanoma-bearing Liběchov Minipigs

Svoboda¹,

Eichlerová²,

Horák³

et al. 2005

Acta Vet. Brno

View full text Add to dashboard Cite

The aim of the study was to investigate the development of haematological indices in the MeLiM strain of miniature pigs. MeLiM minipigs in group M were affected with hereditary malignant melanoma and received 100 mg Fe 3+ dextran i.m. on day 3 of age. Group H contained melanomafree MeLiM minipigs that were supplemented with iron as in group M. Melanoma-free MeLiM minipigs without iron supplementation till the week 5 of age were included in group A. Development of haematological indices in group H was compared to literature data from other breeds and strains of minipigs. Red blood cell indices in group A were found to be characteristic for hypochromic microcytary anaemia. Higher red blood cell counts were found in animals affected with melanoma (group M) on week 8 of age compared to group H. Pigs in group M showed also lower growth intensity compared to healthy animals (group H).Hereditary melanoma, MeLiM, haemoglobin, packed cell volume, iron

show abstract

Section: Development Of Haematological Indices In Group Acontrasting

confidence: 56%

“…According to Kovar et al (1997) tumour cells have high demand for iron. Displacement of normal bone marrow by tumour cells (Kettelhack et al 1994) and increased retention of transferrin in tumour tissue (Aulbert 1989a, b) can also contribute to anaemia development in cancer patients.…”

Section: Development Of Haematological Indices In Group Amentioning

confidence: 99%

Development of Haematological Indices in Melanoma-bearing Liběchov Minipigs

Svoboda¹,

Eichlerová²,

Horák³

et al. 2005

Acta Vet. Brno

View full text Add to dashboard Cite

show abstract

“…The anaemia of chronic disease results from decreased erythrocyte lifespan (about 80 days rather than the normal 120 days), impaired flow of iron from macrophages to plasma and an inadequate erythropoetin response to anaemia (Miller et al, 1990;Abels, 1992a,b;Kushner, 1992;Dshrsen and Hossfeld, 1994). In cancer patients erythropoietin production has been found to be particularly depressed compared with patients with either iron deficiency anaemia or other normochromic, normocytic anaemias associated with chronic disease (Miller et al, 1990;Kettelhack et al, 1994). This may be partly related to the inhibitory effect of increased cytokine production of tumour necrosis factor alpha and interleukin 1 on erythropoesis (Dshrsen and Hossfeld, 1994;Spivak, 1994).…”

mentioning

confidence: 99%

Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

Sweeney

Nicolae²,

Ignacio³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary The purpose of this study was to determine the safety, efficacy and impact on quality of life of recombinant human erythropoietin (r-HuEPO) for cancer patients undergoing radiotherapy (RT). An open-labelled randomized design was used, with patients randomized to either treatment or control arms. Patients in the treatment arm received r-HuEPO given by subcutaneous injection at a dose of 200 units kg-' day-' plus oral iron supplements (ferrous sulphate 325 mg p.o. t.i.d.). Entry was restricted to patients with carcinoma of the lung, uterine cervix, prostate or breast who presented for RT with anaemia parameters reflective of 'the anaemia of chronic disease'. Radiotherapy policies (portals, doses, fraction size, etc.) were determined by the site and stage of disease. Complete blood counts (CBCs) were obtained weekly. The target level of haemoglobin was 15 g dl-1 for men and 14 g dl-1 for women. Quality of life (QOL) was assessed weekly by using an analogue scale to judge energy, activities of daily living and overall quality of life. Forty-eight patients were entered in the study, 24 in the treatment arm and 24 in the control arm. The prerandomization demographic characteristics and mean laboratory values were comparable in both arms. The mean haemoglobin at completion was 13.6 g dl-1 for r-HuEPO-treated patients compared with 11.0 g dl-1 for control subjects (P= 0.0012). Patients who received r-HuEPO demonstrated a mean weekly haemoglobin increase of 0.41 g dl-1 compared with a decrease in mean haemoglobin level in controls for 6 of the 7 weeks of the study (mean weekly decrease of 0.073 g dl-'). Target levels of haemoglobin were achieved by 41.6% of r-HuEPO-treated patients compared with none of the control subjects. The mean platelet count declined in both arms of the study with RT but the decline from pretreatment was less rapid in r-HuEPO-treated patients (11.2% decrease) compared with controls (26.3% decrease) and was statistically significant during weeks 4-6. Toxicity was minor with only mild irritation at the injection site. Mean quality of life end points were superior in the treatment arm but not statistically significant. r-HuEPO had a beneficial effect on weekly haemoglobin levels in patients undergoing RT with response rates similar to other studies. There was also a less rapid decline in weekly platelet counts in r-HuEPO-treated patients compared with control subjects. Further studies are needed to address the optimum dose and scheduling as well as the impact of r-HuEPO on clinical outcomes.

show abstract

Pathophysiology of anemia in cancer

Nowrousian

2008

Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

View full text Add to dashboard Cite

Serum erythropoietin levels in patients with solid tumours

Cited by 8 publications

References 15 publications

Development of Haematological Indices in Melanoma-bearing Liběchov Minipigs

Development of Haematological Indices in Melanoma-bearing Liběchov Minipigs

Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

Pathophysiology of anemia in cancer

Contact Info

Product

Resources

About